Well-funded biotech Moderna Therapeutics has inked a long-term deal with Sweden's Karolinska Institutet to spotlight new applications for the company's messenger RNA technology.
Agilent Technologies is closing its nuclear magnetic resonance business, as the downsizing of its research products division continues. The move is expected to cost 300 jobs over the next 12 months in Santa Clara, CA, and Yarnton, England.
AstraZeneca, two years away from a big relocation to Cambridge, U.K., is broadening its relationship with the local university, signing a slew of new agreements that will bolster its R&D efforts in neuroscience and oncology.
It's become a matter of commonly accepted faith in the biopharma biz that it takes more than $1 billion and 10 years to develop a new drug. Industry associations like to cite that factoid as a reason for the big prices we're seeing on new therapies, often while prodding the FDA for faster action.
Danish drug developer Forward Pharma came through with one of the year's biggest biotech IPOs, raising $221 million to support its plot to battle Biogen Idec in the blockbuster multiple sclerosis market.
Researchers at NC State University and the University of North Carolina have developed a DNA-based delivery vehicle capable of acting as a Trojan horse in cancer cells. Using DNA as a cage instead of synthetic materials makes the vehicle less toxic to healthy cells and allows for the attachment of precise targeting mechanisms.
The self-regulation of insulin delivery is a long-sought goal in the field, spurring the development of closed-loop systems and an artificial pancreas for diabetics. But some researchers are aiming smaller, looking at a way to create stem cells en masse that can produce insulin in response to blood sugar levels.
Japan's Astellas Pharma is the latest big drugmaker allured by the promise of gene therapy, mounting an R&D effort that could lead to a new treatment for an inherited eye disease.
Germany's Wilex has long been on the way out of biotech, but a new collaboration with Roche provides the company with some cash up front and a shot at down-the-line royalties.
Alnylam's in-development RNAi treatment successfully staved off nerve damage related to a rare disease in an ongoing study, the biotech said, early but promising results as the company heads into Phase III with partner Sanofi in tow.